: The investigation concerns whether Dicerna and certain of its officers and/or directors have violated Sections 10 and 20 of the Securities Exchange Act of 1934, according to Market Watch. On June 10, 2015, Seeking Alpha website published a report which stated that "Alnylam Pharmaceuticals ALNY, +0.95% files a lawsuit in Massachusetts against Dicerna Pharmaceuticals accusing it of misappropriating trade secrets Alnylam acquired via its buyout of Sirna Therapeutics from Merck in January 2014. DRNA, +3.47% Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The suit accuses Dicerna of obtaining its trade secrets by hiring six scientists from Merck who were involved in RNAi work, despite each of them signing a confidentiality agreement. It also alleges that certain scientists hired by Dicerna were seen taking material out of the Merck facility prior to their departure." On this news, shares of Dicerna fell $0.88 per share, to $15.22, or more than 5.47%, in after-hours trading on June 10, 2015. It alleges that Dicerna subsequent product candidates and delivery technologies are 'strikingly similar' to Sirna's/Merck's.
(news.financializer.com). As
reported in the news.
Tagged under , Merck topics.